# Long-term outcomes of two-stage revision with positive cultures at reimplantation

**Authors:** Caterina Rocchi, Carmine Fabio Bruno, Rocco Cannata, Katia Chiappetta, Guido Grappiolo, Mattia Loppini

PMC · DOI: 10.1007/s00402-026-06236-0 · Archives of Orthopaedic and Trauma Surgery · 2026-02-26

## TL;DR

The study found that having positive cultures during reimplantation in joint revision surgery does not predict worse outcomes, while higher BMI is linked to increased failure risk.

## Contribution

This study provides new evidence that positive cultures at reimplantation do not predict treatment failure in two-stage revision surgery.

## Key findings

- Elevated BMI was the only significant predictor of treatment failure.
- Positive cultures at reimplantation were not associated with increased failure risk.
- Clinical outcomes were not significantly affected by the presence or number of positive cultures.

## Abstract

microbiological eradication after two-stage revision is not obtained in up to 18% of cases, yet the prognostic value of positive cultures at reimplantation remains controversial. The primary aim of the study was to evaluate outcomes of patients with positive cultures at second stage, identifying failure predictors. The secondary outcome was to compare reintervention-free survival.

this retrospective cohort study included patients treated using a two-stage protocol between 2016 and 2022. PJI was diagnosed using MSIS 2013 criteria, and treatment failure was defined according to a Delphi-based consensus. Cox regression analysis was employed to assess risk factors for failure, including Charlson Comorbidity Index (CCI); American Society of Anesthesiologists (ASA) score; age; time to reimplantation; joint; number of previous septic revisions; positive cultures number at reimplantation; a difficult to treat organism.

83 cases were reviewed (63 hips, 20 knees). The average interval between stages was 181 days. Over 6 years follow-up (FU), elevated BMI was the only significant predictor of failure (HR 1.19; 95% CI 1.02–1.39; p = 0.03). In contrast, positive cultures at reimplantation were not associated with an increased failure risk (p = 0.95), even in cases with multiple positive cultures (p = 0.72).

elevated BMI at reimplantation was independently associated with subsequent failure. Clinical outcomes were not significantly associated with the presence or number of positive cultures, although smaller effects cannot be excluded given the limited sample size. These findings emphasize the importance of a patient-focused rather than culture-centered approach.

III.

## Linked entities

- **Diseases:** PJI (MONDO:0017380)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** Musculoskeletal Infection (MESH:D009140), Coagulase-negative staphylococci (MESH:D064726), renal disease (MESH:D007674), heart failure (MESH:D006333), hemiplegia (MESH:D006429), dementia (MESH:D003704), HIV/AIDS (MESH:D015658), dislocation (MESH:D004204), chronic pulmonary disease (MESH:D002908), polymicrobial (MESH:D060085), CCI (MESH:C566784), rheumatoid arthritis (MESH:D001172), connective tissue disease (MESH:D003240), type C (OMIM:211750), infected (MESH:D007239), stem (MESH:D020295), myocardial infarction (MESH:D009203), cerebrovascular disease (MESH:D002561), joint stiffness (MESH:C535724), obese (MESH:D009765), stroke (MESH:D020521), shoulder arthroplasty (MESH:D000070599), dislocation of the acetabular (OMIM:142700), PJI (MESH:D057068), liver disease (MESH:D008107), muscle atrophy (MESH:D009133), injury (MESH:D014947), pain (MESH:D010146), fracture (MESH:D050723), PJI (MESH:C537702), cancer (MESH:D009369), diabetes (MESH:D003920)
- **Chemicals:** cefazolin (MESH:D002437), MSSAMethicillin (-), piperacillin/tazobactam (MESH:D000077725), vancomycin (MESH:D014640), levofloxacin (MESH:D064704), gentamycin (MESH:D005839), Methicillin (MESH:D008712)
- **Species:** Staphylococcus capitis (species) [taxon 29388], Staphylococcus aureus (species) [taxon 1280], Staphylococcus pasteuri (species) [taxon 45972], Proteus mirabilis (species) [taxon 584], Homo sapiens (human, species) [taxon 9606], Staphylococcus epidermidis (species) [taxon 1282], Enterobacter cloacae (species) [taxon 550], Enterococcus faecalis (species) [taxon 1351], Candida albicans (species) [taxon 5476]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946312/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946312/full.md

---
Source: https://tomesphere.com/paper/PMC12946312